Novator

Novator Partners is an international investment firm founded in 2004 by Icelandic billionaire Thor Björgólfsson. While the firm operates across multiple sectors including telecommunications and technology, it has a significant historical and ongoing presence in the life sciences and pharmaceutical industries. Novator is most notably recognized for its instrumental role in the growth of Actavis, which it helped transform into one of the world's largest generic pharmaceutical companies before its eventual sale. The firm continues to manage a diverse portfolio that includes strategic investments in biotech and healthcare companies, focusing on high-growth opportunities and restructuring plays.